We are live on ! Find out more
XBIT icon

XBiotech

43 hedge funds and large institutions have $16.9M invested in XBiotech in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more capital invested

Capital invested by funds: $13M → $16.9M (+$3.91M)

0.4% less ownership

Funds ownership: 9.33%8.93% (-0.4%)

6% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 16

2% less funds holding

Funds holding: 4443 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

36% less call options, than puts

Call options by funds: $207K | Put options by funds: $325K

Holders
43
Holders Change
-1
Holders Change %
-2.27%
% of All Funds
0.99%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
15
Reduced
16
Closed
4
Calls
$207K
Puts
$325K
Net Calls
-$118K
Net Calls Change
+$458K
Name Holding Trade Value Shares
Change
Change in
Stake
ARTA
26
A.R.T. Advisors
New York
$74K -$52.4K -11,378 -45%
AIG
27
American International Group
New York
$66K -$3.06K -663 -5%
VOYA Investment Management
28
VOYA Investment Management
Georgia
$55K
State of Wisconsin Investment Board
29
State of Wisconsin Investment Board
Wisconsin
$53K
Simplex Trading
30
Simplex Trading
Illinois
$33K +$29.1K +6,310 New
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$26K +$21.4K +4,645 +1,881%
BNP Paribas Financial Markets
32
BNP Paribas Financial Markets
France
$25.2K +$866 +188 +4%
JP Morgan Chase
33
JP Morgan Chase
New York
$21K -$1.28K -279 -7%
Barclays
34
Barclays
United Kingdom
$21K +$78 +17 +0.4%
Legal & General Group
35
Legal & General Group
United Kingdom
$15K -$12.4K -2,702 -49%
Citigroup
36
Citigroup
New York
$14K +$2.42K +525 +26%
Manulife (Manufacturers Life Insurance)
37
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$9K -$17.5K -3,793 -68%
Bank of America
38
Bank of America
North Carolina
$8K -$77.2K -16,758 -92%
CG
39
Cutler Group
California
$8K +$5.69K +1,235 +412%
AIP
40
Ameritas Investment Partners
Nebraska
$7K
GRP
41
Global Retirement Partners
California
$2K +$1.43K +310 New
Bank of Montreal
42
Bank of Montreal
Ontario, Canada
$1K -$140K -30,350 -100%
UBS Group
43
UBS Group
Switzerland
$1K +$880 +191 New
Millennium Management
44
Millennium Management
New York
-$86K -21,714 Closed
TRCT
45
Tower Research Capital (TRC)
New York
-$17K -4,421 Closed
Parallax Volatility Advisers
46
Parallax Volatility Advisers
California
-$13K -3,192 Closed
SIC
47
Salem Investment Counselors
North Carolina
-$2K -500 Closed

XBIT Hedge Fund Activity: Q1 2018 in Review

43 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2018, worth a combined $16.9M — up 30% from $13M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of XBIT and 3 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 15 added.

The largest buyer was Dimensional Fund Advisors, adding an estimated $55.7K. The largest seller was Goldman Sachs, cutting an estimated $260K.

  • 43 institutional investors held XBiotech (XBIT) as of Q1 2018, down from 44 in Q4 2017.
  • Funds reported $16.9M of XBiotech stock for Q1 2018, up 30% quarter-over-quarter.
  • 3 funds opened new XBiotech positions in Q1 2018 and 4 closed out, a net change of -1 holder.
  • The largest XBiotech buyer in Q1 2018 was Dimensional Fund Advisors, an estimated $55.7K added.
  • The largest XBiotech seller in Q1 2018 was Goldman Sachs, an estimated $260K sold.

Based on aggregated 13F filings for Q1 2018.